<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2024-9.1.10</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-4603</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group></article-categories><title-group><article-title>Перспективы применения ультразвука различной интенсивности для лечения пациентов со злокачественными глиомами головного мозга</article-title><trans-title-group xml:lang="en"><trans-title>Prospects for using ultrasound of various intensity for  the  treatment of  patients with  malignant brain gliomas</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0219-7260</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Регентова</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Regentova</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Регентова Ольга Сергеевна – кандидат медицинских наук, заведующая отделением лучевой терапии детей с койками онкологии, </p><p>117997, г. Москва, ул. Профсоюзная, 86</p></bio><bio xml:lang="en"><p>Olga S. Regentova – Cand. Sc. (Med.), Head of the Department of Pediatric Radiation Oncology with oncology beds, </p><p>Profsoyuznaya str. 86, Moscow 117997</p></bio><email xlink:type="simple">olgagraudensh@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9249-9272</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пархоменко</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Parkhomenko</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пархоменко Роман Алексеевич – доктор медицинских наук, ведущий научный сотрудник лаборатории лучевой терапии и комплексных методов лечения онкологических заболеваний, 117997, г. Москва, ул. Профсоюзная, 86;</p><p>профессор кафедры онкологии и рентгенорадиологии Медицинского института, 117198, г. Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Roman A. Parkhomenko – Dr. Sc. (Med.), Leading Research Officer at the Laboratory of Radiation Therapy and Complex Methods for Cancer Treatment, Profsoyuznaya str. 86, Moscow 117997;</p><p>Professor at the Department of Oncology and Radiology, Miklukho-Maklaya str. 6, Moscow 117198</p></bio><email xlink:type="simple">mailbox@rncrr.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0786-5448</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербенко</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcherbenko</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щербенко Олег Ильич – доктор медицинских наук, профессор, главный научный сотрудник лаборатории лучевой терапии и комплексных методов лечения онкологических заболеваний, </p><p>117997, г. Москва, ул. Профсоюзная, 86</p></bio><bio xml:lang="en"><p>Oleg I. Shcherbenko – Dr. Sc. (Med.), Chief Research Officer at the Laboratory of Radiation Therapy and Complex Methods for Cancer Treatment, </p><p>Profsoyuznaya str. 86, Moscow 117997</p></bio><email xlink:type="simple">mailbox@rncrr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5900-6755</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антоненко</surname><given-names>Ф. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Antonenko</surname><given-names>F. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Антоненко Федор Федорович – доктор медицинских наук, профессор, член-корреспондент РАН, заведующий лабораторией лучевой терапии и комплексных методов лечения онкологических заболеваний, </p><p>117997, г. Москва, ул. Профсоюзная, 86</p></bio><bio xml:lang="en"><p>Fedor F. Antonenko – Dr. Sc. (Med.), Professor, Corresponding Member of RAS, Head of the Laboratory of Radiation Therapy and Complex Methods for Cancer Treatment, </p><p>Profsoyuznaya str. 86, Moscow 117997</p></bio><email xlink:type="simple">antonenkoff@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-5380-2056</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зелинская</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Zelinskaya</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зелинская Наталья Ивановна – кандидат медицинских наук, старший научный сотрудник лаборатории лучевой терапии и комплексных методов лечения онкологических заболеваний, </p><p>117997, г. Москва, ул. Профсоюзная, 86</p></bio><bio xml:lang="en"><p>Natalia I. Zelinskaya – Cand. Sc. (Med.), Senior Research Officer at the Laboratory of Radiation Therapy and Complex Methods for Cancer Treatment, </p><p>Profsoyuznaya str. 86, Moscow 117997</p></bio><email xlink:type="simple">natzelinskaya49@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5556-0166</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сидибе</surname><given-names>Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sidibe</surname><given-names>N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сидибе Нелли – врач-радиотерапевт отделения лучевой терапии детей с  койками онкологии, </p><p>117997, г. Москва, ул. Профсоюзная, 86</p></bio><bio xml:lang="en"><p>Nelly Sidibe – Radiation Oncologist at the Department of Pediatric Radiation Oncology with oncology beds, </p><p>Profsoyuznaya str. 86, Moscow 117997</p></bio><email xlink:type="simple">nellysidibe@rncrr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6661-0280</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полушкин</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Polushkin</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полушкин Павел Владимирович – кандидат медицинских наук, врач-радиотерапевт отделения лучевой терапии детей с койками онкологии, научный сотрудник лаборатории лучевой терапии и комплексных методов лечения онкологических заболеваний, </p><p>117997, г. Москва, ул. Профсоюзная, 86</p></bio><bio xml:lang="en"><p>Pavel V. Polushkin – Cand. Sc. (Med.), Radiation Oncologist at the Department of Pediatric Radiation Oncology with oncology beds, Research Officer at the Laboratory of Radiation Therapy and Complex Methods for Cancer Treatment,</p><p>Profsoyuznaya str. 86, Moscow 117997</p></bio><email xlink:type="simple">ppolushkin.93@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1641-6452</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Солодкий</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Solodkiy</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Солодкий Владимир Алексеевич – доктор медицинских наук, профессор, академик РАН, директор, </p><p>117997, г. Москва, ул. Профсоюзная, 86</p></bio><bio xml:lang="en"><p>Vladimir A. Solodkiy – Dr. Sc. (Med.), Professor, Member of RAS, Director, </p><p>Profsoyuznaya str. 86, Moscow 117997</p></bio><email xlink:type="simple">mailbox@rncrr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России</institution></aff><aff xml:lang="en"><institution>Russian Scientific Center of Roentgenoradiology</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Российский научный центр рентгенорадиологии» Минздрава России;&#13;
ФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»</institution></aff><aff xml:lang="en"><institution>Russian Scientific Center of Roentgenoradiology;&#13;
Peoples’ Friendship University of Russia named after Patrice Lumumba</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>03</month><year>2024</year></pub-date><volume>9</volume><issue>1</issue><fpage>96</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Регентова О.С., Пархоменко Р.А., Щербенко О.И., Антоненко Ф.Ф., Зелинская Н.И., Сидибе Н., Полушкин П.В., Солодкий В.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Регентова О.С., Пархоменко Р.А., Щербенко О.И., Антоненко Ф.Ф., Зелинская Н.И., Сидибе Н., Полушкин П.В., Солодкий В.А.</copyright-holder><copyright-holder xml:lang="en">Regentova O.S., Parkhomenko R.A., Shcherbenko O.I., Antonenko F.F., Zelinskaya N.I., Sidibe N., Polushkin P.V., Solodkiy V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/4603">https://www.actabiomedica.ru/jour/article/view/4603</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Лечение злокачественных глиом головного мозга включает хирургическое вмешательство, лучевую терапию и химиотерапию с темозоломидом. Однако данное комплексное лечение не предотвращает рецидивы и прогрессирование опухоли, что обусловлено активностью опухолевых клеток и высокой мутационной нагрузкой. Исследователи экспериментируют с  фокусированным ультразвуком (ФУЗ) различной интенсивности в лечении глиобластомы (ГБМ). ФУЗ показал обнадёживающие результаты в клинических исследованиях.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. В настоящем обзоре приводятся краткие данные об истории становления указанного метода, результатах его применения в экспериментах и клинических испытаниях, а также основные возможные направления его  внедрения в  нейроонкологии, в  частности, для  лечения глиобластом, в зависимости от параметров, включая частоту, мощность, длительность импульса и рабочий цикл.</p></sec><sec><title>Методы</title><p>Методы. Проведены анализ и  интерпретация имеющихся публикаций, для поиска которых использовалась база данных PubMed и ключевые слова «focused ultrasound, glioma, HIFU, LIFU», а также поисковые системы Яндекс и Google и ключевые слова «фокусированный ультразвук, глиомы, HIFU, LIFU».</p></sec><sec><title>Результаты</title><p>Результаты. ФУЗ низкой интенсивности можно использовать для временного открытия гематоэнцефалического барьера (ГЭБ), который ограничивает диффузию большинства макромолекул и терапевтических агентов в мозг. Высокоинтенсивный ФУЗ может вызвать абляцию опухоли за счёт гипертермического эффекта, а также стимулировать иммунологическую атаку опухолевых клеток, активировать соносенсибилизаторы для  оказания цитотоксического воздействия на опухолевую ткань и может повышать чувствительность опухолей к лучевой терапии. Гистотрипсия вызывает абляцию опухоли посредством акустической кавитации.</p></sec><sec><title>Заключение</title><p>Заключение. Фокусированный ультразвук является многообещающим потенциальным методом лечения глиом. Дальнейшее изучение в  виде клинических испытаний должно определить оптимальные параметры ультразвука для достижения эффективности лечения пациентов со злокачественными опухолями головного мозга.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Treatment for malignant brain gliomas includes surgery, radiation therapy, and chemotherapy with temozolomide. However, this complex treatment does not prevent tumor relapses and progression, which is caused by the activity of tumor cells and a high mutational burden. Researchers are experimenting with different intensity of focused ultrasound (FUS) in the treatment of glioblastoma (GBM). FUS has shown encouraging results in clinical studies.</p></sec><sec><title>The aim of the study</title><p>The aim of the study. This review presents brief information on the history of the development of  the studied method, the  results of  its  application in  experiments and   clinical trials, as  well  as the  main possible directions for  its  implementation in  neuro-oncology, in  particular, for  the  treatment of  glioblastomas, depending on parameters, including frequency, power, pulse duration and duty cycle.</p></sec><sec><title>Methods</title><p>Methods. We carried out an analysis and interpretation of existing publications; for the search, we used the PubMed database and the keywords “focused ultrasound, glioma, HIFU, LIFU”, as  well  as Yandex and  Google search engines and  the  same keywords in Russian.</p></sec><sec><title>Results</title><p>Results. Low-intensity FUS can be used to temporarily open the blood-brain barrier (BBB), which limits the diffusion of most macromolecules and therapeutic agents into the brain. High-intensity FUS can cause tumor ablation due to a hyperthermic effect, and also stimulate an immunological attack of tumor cells, activate sonosensitizers to exert a cytotoxic effect on tumor tissue, and can increase the sensitivity of tumors to radiation therapy. Histotripsy causes tumor ablation through acoustic cavitation.</p></sec><sec><title>Conclusion</title><p>Conclusion. Focused ultrasound is a promising potential treatment for gliomas. Further study in the form of clinical trials should determine the optimal ultrasound parameters to achieve effective treatment for patients with malignant brain tumors.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>онкология</kwd><kwd>фокусированный ультразвук различных интенсивностей</kwd><kwd>детская онкология</kwd><kwd>нейроонкология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oncology</kwd><kwd>focused ultrasound of various intensity</kwd><kwd>pediatric oncology</kwd><kwd>neuro-oncology</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Parekh K, LeBlang S, Nazarian J, Mueller S, Zacharoulis S, Hynynen K, et al. Past, present and future of focused ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting. Neoplasia. 2023; 37: 100876. doi: 10.1016/j.neo.2023.100876</mixed-citation><mixed-citation xml:lang="en">Parekh K, LeBlang S, Nazarian J, Mueller S, Zacharoulis S, Hynynen K, et al. Past, present and future of focused ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of  the  2021 FUSF DIPG meeting. Neoplasia. 2023; 37: 100876. doi: 10.1016/j.neo.2023.100876</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Озеров С.С., Рыжова М.В., Кумирова Э.В. Диффузные опухоли ствола головного мозга у детей. Биология опухоли и надежда на лучший исход. Современное состояние проблемы. Вопросы нейрохирургии им. Н.Н. Бурденко. 2021; 4: 77-86. doi: 10.17116/neiro20218504177</mixed-citation><mixed-citation xml:lang="en">Ozerov SS, Ryzhova MV, Kumirova EV. Diffuse brainstem tumors in  children. Tumor biology and  hope for  a  better outcome. Current state of  the  problem. Zhurnal Voprosy Neirokhirurgii Imeni N.N. Burdenko. 2021; 4: 77-86. (In Russ.). doi: 10.17116/neiro20218504177</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman L, Brown C, Badie B. Chimeric antigen receptor (CAR) T cell therapy for glioblastoma. Neuromolecular Med. 2022; 2021: 1-6. doi: 10.1007/s12017-021-08689-5</mixed-citation><mixed-citation xml:lang="en">Feldman L, Brown C, Badie B. Chimeric antigen receptor (CAR) T cell therapy for glioblastoma. Neuromolecular Med. 2022; 2021: 1-6. doi: 10.1007/s12017-021-08689-5</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yoo HJ, Harapan BN. Chimeric antigen receptor (CAR) immunotherapy: Basic principles, current advances, and future prospects in neuro-oncology. Immunologic Res. 2021; 69(6): 471- 486. doi: 10.1007/s12026-021-09236-x</mixed-citation><mixed-citation xml:lang="en">Yoo  HJ, Harapan  BN. Chimeric antigen receptor (CAR) immunotherapy: Basic principles, current advances, and  future prospects in neuro-oncology. Immunologic Res. 2021; 69(6): 471- 486. doi: 10.1007/s12026-021-09236-x</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fu W, Wang W, Li H, Jiao Y, Huo R, Yan Z, et al. Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma. Front Immunol. 2020; 11: 835. doi: 10.3389/fimmu.2020.00835</mixed-citation><mixed-citation xml:lang="en">Fu W, Wang W, Li H, Jiao Y, Huo R, Yan Z, et al. Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma. Front Immunol. 2020; 11: 835. doi: 10.3389/fimmu.2020.00835</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shen SH, Woroniecka K, Barbour AB, Fecci PE, SanchezPerez L, Sampson JH, et al. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020; 20(6): 579-591. doi: 10.1080/14712598.2020.1727436</mixed-citation><mixed-citation xml:lang="en">Shen SH, Woroniecka  K, Barbour  AB, Fecci  PE, SanchezPerez L, Sampson JH, et al. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020; 20(6): 579-591. doi: 10.1080/14712598.2020.1727436</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Xiong Q, Zhu J, Zhang Y, Deng H. CAR-NK cell therapy for glioblastoma: What to do next? Front Oncol. 2023; 13: 1192128. doi: 10.3389/fonc.2023.1192128</mixed-citation><mixed-citation xml:lang="en">Xiong Q, Zhu  J, Zhang Y, Deng  H. CAR-NK cell therapy for glioblastoma: What to do next? Front Oncol. 2023; 13: 1192128. doi: 10.3389/fonc.2023.1192128</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Stavrakaki E, Dirven CMF, Lamfers MLM. Personalizing oncolytic virotherapy for glioblastoma: In search of biomarkers for response. Cancers (Basel). 2021; 13(4): 614. doi: 10.3390/cancers13040614</mixed-citation><mixed-citation xml:lang="en">Stavrakaki  E, Dirven  CMF, Lamfers  MLM. Personalizing oncolytic virotherapy for  glioblastoma: In  search of  biomarkers for response. Cancers (Basel). 2021; 13(4): 614. doi: 10.3390/cancers13040614</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6): 360-378. doi: 10.1038/s41568-021-00346-0 10. ter Haar G. The history of focused ultrasound. URL: https://www.fusfoundation.org/posts/the-history-of-focused-ultrasound [date of access: 11.03.2021].</mixed-citation><mixed-citation xml:lang="en">Saxena  M, van  der  Burg  SH, Melief  CJM, Bhardwaj  N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6): 360-378. doi: 10.1038/s41568-021-00346-0 10. ter Haar G. The history of focused ultrasound. URL: https://www.fusfoundation.org/posts/the-history-of-focused-ultrasound [date of access: 11.03.2021].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Лаборатория медицинского и промышленного ультразвука. URL: http://limu.msu.ru [дата доступа: 1.11.2023].</mixed-citation><mixed-citation xml:lang="en">Laboratory for Industrial and Medical Ultrasound. (In Russ.). URL: http://limu.msu.ru.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Назаренко Г.И., Чен В.Ш., Джан Л., Хитрова А.Н., Пащенко Н.В. Ультразвуковая абляция как высокотехнологичная органосохраняющая альтернатива хирургической операции. URL: https://oncology.ru/specialist/journal_oncology/archive/0209/018.pdf [дата доступа: 31.10.2023].</mixed-citation><mixed-citation xml:lang="en">Nazarenko GI, Chen VS, Dzhan L, Khitrova AN, Paschenko NV. Ultrasonic ablation as a high-tech organ-preserving an alternative to surgery. (In Russ.) URL: https://oncology.ru/specialist/journal_oncology/archive/0209/018.pdf [дата доступа: 31.10.2023].</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Q, Zhou Y, Chen J, Huang N, Wang Z, Cheng Y. Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. IntJ Nanomedicine. 2021; 16: 185-199. doi: 10.2147/IJN.S286221</mixed-citation><mixed-citation xml:lang="en">Yang Q, Zhou Y, Chen J, Huang N, Wang Z, Cheng Y. Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. IntJ Nanomedicine. 2021; 16: 185-199. doi: 10.2147/IJN.S286221</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng Q, Xia B, Huang X, Luo J, Zhong S, Li X. Nanomedicines for high intensity focused ultrasound cancer treatment and theranostics (review). Exp Ther Med. 2023; 25(4): 170. doi: 10.3892/etm.2023.11869</mixed-citation><mixed-citation xml:lang="en">Zheng Q, Xia B, Huang X, Luo J, Zhong S, Li X. Nanomedicines for high intensity focused ultrasound cancer treatment and theranostics (review). Exp Ther Med. 2023; 25(4): 170. doi: 10.3892/etm.2023.11869</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Пономарчук Е.М., Буравков С.В., Ванг Я.Н, Хохлова Т.Д., Хохлова В.А. Морфологический анализ разрушений биологической ткани при облучении мощными фокусированными ультразвуковыми импульсами с ударными фронтами. Ученые записки физического факультета МГУ. 2016; 4: 164701</mixed-citation><mixed-citation xml:lang="en">Ponomarchuk EM, Buravkov SV, Wang YaN, Khokhlova TD, Khokhlova VA. Morphological analysis of biological tissue lesions induced by  high intensity focused ultrasound pulses containing shock fronts. Memoirs of the Faculty of Physics Lomonosov Moscow State University. 2016; 4: 164701. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lamsam L, Johnson E, Connolly ID, Wintermark M, Hayden Gephart M. A review of potential applications of MRguided focused ultrasound for targeting brain tumor therapy. Neurosurg Focus. 2018; 44(2): 10. doi: 10.3171/2017.11.FOCUS17620</mixed-citation><mixed-citation xml:lang="en">Lamsam  L, Johnson  E, Connolly  ID, Wintermark  M, Hayden  Gephart  M. A  review of  potential applications of  MRguided focused ultrasound for  targeting brain tumor therapy. Neurosurg Focus. 2018; 44(2): 10. doi: 10.3171/2017.11.FOCUS17620</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Roberts JW, Powlovich L, Sheybani N, LeBlang S. Focused ultrasound for the treatment of glioblastoma. J Neurooncol. 2022; 157(2): 237-247. doi: 10.1007/s11060-022-03974-0</mixed-citation><mixed-citation xml:lang="en">Roberts JW, Powlovich L, Sheybani N, LeBlang S. Focused ultrasound for the treatment of glioblastoma. J Neurooncol. 2022; 157(2): 237-247. doi: 10.1007/s11060-022-03974-0</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Галимова Р.М., Иллариошкин С.Н., Бузаев И.В., Качемаева О.В. Терапия двигательных нарушений методом фокусированного ультразвука под контролем магнитно-резонансной томографии. Рекомендации для врачей-неврологов по отбору пациентов. Новые технологии. 2020; 1: 9-15. doi: 10.24411/2226-079X-2020-12168</mixed-citation><mixed-citation xml:lang="en">Galimova RM, Illarioshkin SN, Buzaev IV, Kachemaeva OV. Therapy of motor disorders by focused ultrasound under the control of magnetic resonance imaging. Recommendations for neurologists on patient selection. Novye tekhnologii. 2020; 1: 9-15. (In Russ.). doi: 10.24411/2226-079X-2020-12168</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Janwadkar R, Leblang S, Ghanouni P, Brenner J, Ragheb J, Hennekens CH, et al. Focused ultrasound for pediatric diseases. Pediatrics. 2022; 149(3): e2021052714. doi: 10.1542/peds.2021-05271</mixed-citation><mixed-citation xml:lang="en">Janwadkar R, Leblang S, Ghanouni P, Brenner J, Ragheb J, Hennekens CH, et al. Focused ultrasound for pediatric diseases. Pediatrics. 2022; 149(3): e2021052714. doi:  10.1542/peds.2021-05271</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Москвичева Л.И. Применение HIFU-терапии в онкологии (2000–2021 гг.). Онкология. Журнал им. П.А. Герцена. 2022; 11(1): 64-74. doi: 10.17116/onkolog20221101164</mixed-citation><mixed-citation xml:lang="en">Moskvicheva LI. Application of HIFU therapy in oncology (2000–2021). P.A. Herzen Journal of Oncology. 2022; 11(1): 6474. (In Russ.). doi: 10.17116/onkolog20221101164</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bachu VS, Kedda J, Suk I, Green JJ, Tyler B. High-intensity focused ultrasound: A review of mechanisms and clinical applications. Ann Biomed Eng. 2021; 49(9): 1975-1991. doi: 10.1007/s10439-021-02833-9</mixed-citation><mixed-citation xml:lang="en">Bachu VS, Kedda J, Suk I, Green JJ, Tyler B. High-intensity focused ultrasound: A review of mechanisms and clinical applications. Ann Biomed Eng. 2021; 49(9): 1975-1991. doi:  10.1007/s10439-021-02833-9</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Галкин М.В. Применение транскраниального фокусированного ультразвука в лечении патологии ЦНС. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2016; 80(2): 108-118. doi: 10.17116/neiro2016802108-118</mixed-citation><mixed-citation xml:lang="en">Galkin MV. The use of transcranial focused ultrasound in CNS diseases. Zhurnal Voprosy Neirokhirurgii Imeni N.N. Burdenko. 2016; 80(2): 108-118. (In Russ.). doi: 10.17116/neiro2016802108-118</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Paun L, Moiraghi A, Jannelli G, Nouri A, DiMeco F, Pallud J, et al. From focused ultrasound tumor ablation to brain blood barrier opening for high grade glioma: A systematic review. Cancers (Basel). 2021; 13(22): 5614. doi: 10.3390/cancers13225614</mixed-citation><mixed-citation xml:lang="en">Paun L, Moiraghi A, Jannelli G, Nouri A, DiMeco F, Pallud J, et al. From focused ultrasound tumor ablation to brain blood barrier opening for high grade glioma: A systematic review. Cancers (Basel). 2021; 13(22): 5614. doi: 10.3390/cancers13225614</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Duryea AP, Hall TL, Maxwel AD, Zhen X, Cain CA, et al. Histotripsy erosion of model urinary calculi. J Endourol. 2011; 25(2): 341-344. doi: 10.1089/end.2010.0407</mixed-citation><mixed-citation xml:lang="en">Duryea  AP, Hall TL, Maxwel  AD, Zhen  X, Cain  CA, et  al. Histotripsy erosion of model urinary calculi. J Endourol. 2011; 25(2): 341-344. doi: 10.1089/end.2010.0407</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sukovich JR, Cain CA, Pandey AS, Chaudhary N, CameloPiragua S, Allen SP, et al. In vivo histotripsy brain treatment. J Neurosurg. 2018; 131(4): 1-8. doi: 10.3171/2018.4.JNS172652</mixed-citation><mixed-citation xml:lang="en">Sukovich JR, Cain CA, Pandey AS, Chaudhary N, CameloPiragua S, Allen SP, et al. In vivo histotripsy brain treatment. J Neurosurg. 2018; 131(4): 1-8. doi: 10.3171/2018.4.JNS172652</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Choi SW, Duclos S, Camelo-Piragua S, Chaudhary N, Sukovich J, Hall T, et al. Histotripsy treatment of murine brain and glioma: Temporal profile of magnetic resonance imaging and histological characteristics post-treatment. Ultrasound Med Biol. 2023; S0301- 5629(23)00148-5. doi: 10.1016/j.ultrasmedbio.2023.05.002</mixed-citation><mixed-citation xml:lang="en">Choi SW, Duclos S, Camelo-Piragua S, Chaudhary N, Sukovich J, Hall T, et al. Histotripsy treatment of murine brain and glioma: Temporal profile of magnetic resonance imaging and histological characteristics post-treatment. Ultrasound Med Biol. 2023; S0301- 5629(23)00148-5. doi: 10.1016/j.ultrasmedbio.2023.05.002</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hendricks-Wenger A, Hutchison R, Vlaisavljevich E, Allen IC. Immunological effects of histotripsy for cancer therapy. Front Oncol. 2021; 11: 681629. doi: 10.3389/fonc.2021.681629</mixed-citation><mixed-citation xml:lang="en">Hendricks-Wenger  A, Hutchison  R, Vlaisavljevich  E, Allen IC. Immunological effects of histotripsy for cancer therapy. Front Oncol. 2021; 11: 681629. doi: 10.3389/fonc.2021.681629</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Deligne C, Hachani J, Duban-Deweer S, Meignan S, Leblond P, Carcaboso AM, et al. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS. 2020; 17: 37. doi: 10.1186/s12987-020-00198-0</mixed-citation><mixed-citation xml:lang="en">Deligne  C, Hachani  J, Duban-Deweer  S, Meignan  S, Leblond P, Carcaboso AM, et al. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to  better understand the  chemoresistance. Fluids Barriers CNS. 2020; 17: 37. doi: 10.1186/s12987-020-00198-0</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Angeli E, Nguyen TT, Janin A, Bousquet G. How to make anticancer drugs cross the blood-brain barrier to treat brain metastases. Int J Mol Sci. 2019; 21(1): 22. doi: 10.3390/ijms21010022</mixed-citation><mixed-citation xml:lang="en">Angeli E, Nguyen TT, Janin A, Bousquet G. How to make anticancer drugs cross the blood-brain barrier to treat brain metastases. Int J Mol Sci. 2019; 21(1): 22. doi: 10.3390/ijms21010022</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Воропаева Е.Н., Карпова В.С., Поспелова Т.И., Максимов В.Н., Воронцова Е.В. Современные представления о роли гематоэнцефалического барьера в развитии лимфом центральной нервной системы. Journal of Siberian Medical Sciences. 2022; (2): 131-147. doi: 10.31549/2542-1174-2022-6-2-131-147</mixed-citation><mixed-citation xml:lang="en">Voropaeva EV, Karpova VS, Pospelova TI, Maksimov VN, Vorontsova  EV. Current research on  the role of the blood-brain barrier in the central nervous system lymphomas development. Journal of Siberian Medical Sciences. 2022; (2): 131-147. (In Russ.). doi: 10.31549/2542-1174-2022-6-2-131-147</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Brighi C, Reid L, White AL, Genovesi LA, Kojic M, Millar A, et al. MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma. Neurooncol Adv. 2020; 2(1): vdaa030. doi: 10.1093/noajnl/vdaa030</mixed-citation><mixed-citation xml:lang="en">Brighi C, Reid L, White AL, Genovesi LA, Kojic M, Millar A, et al. MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma. Neurooncol Adv. 2020; 2(1): vdaa030. doi: 10.1093/noajnl/vdaa030</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Bunevicius A, McDannold NJ, Golby AJ. Focused ultrasound strategies for brain tumor therapy. Oper Neurosurg (Hagerstown). 2020; 19(1): 9-18. doi: 10.1093/ons/opz374</mixed-citation><mixed-citation xml:lang="en">Bunevicius A, McDannold  NJ, Golby  AJ. Focused ultrasound strategies for brain tumor therapy. Oper Neurosurg (Hagerstown). 2020; 19(1): 9-18. doi: 10.1093/ons/opz374</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: Potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009; 15: 7092-7098. doi: 10.1158/1078-0432.CCR-09-1349</mixed-citation><mixed-citation xml:lang="en">Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: Potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009; 15: 7092-7098. doi: 10.1158/1078-0432.CCR-09-1349</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Bérard C, Truillet C, Larrat B, Dhermain F, Estève MA, Correard F, et al. Anticancer drug delivery by focused ultrasoundmediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside. Pharmacol Ther. 2023; 250: 108518. doi: 10.1016/j.pharmthera.2023.108518</mixed-citation><mixed-citation xml:lang="en">Bérard  C, Truillet  C, Larrat  B, Dhermain  F, Estève  MA, Correard F, et al. Anticancer drug delivery by focused ultrasoundmediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside. Pharmacol Ther. 2023; 250: 108518. doi: 10.1016/j.pharmthera.2023.108518</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Alli S, Figueiredo CA, Golbourn B, Sabha N, Wu MY, Bondoc A, et al. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery. J Control Release. 2018; 281: 29-41. doi: 10.1016/j. jconrel.2018.05.005</mixed-citation><mixed-citation xml:lang="en">Alli S, Figueiredo CA, Golbourn B, Sabha N, Wu MY, Bondoc A, et al. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery. J Control Release. 2018; 281: 29-41. doi: 10.1016/j. jconrel.2018.05.005</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">van Vuurden. Van Vuurden group. The Princess Maxima Center. URL: https://research.prinsesmaximacentrum.nl/en/research-groups/van-vuurden-group [date of access: 31.10.2023].</mixed-citation><mixed-citation xml:lang="en">van Vuurden. Van Vuurden group. The Princess Maxima Center. URL:  https://research.prinsesmaximacentrum.nl/en/ research-groups/van-vuurden-group [date of access: 31.10.2023].</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">t’ Hart E, Bianco J, Bruin MAC, Derieppe M, Besse HC, Berkhout K, et al. Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. J Control Release. 2023; 357: 287-298. doi: 10.1016/j.jconrel.2023.03.058</mixed-citation><mixed-citation xml:lang="en">t’  Hart  E, Bianco  J, Bruin  MAC, Derieppe  M, Besse  HC, Berkhout K, et al. Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. J Control Release. 2023; 357: 287-298. doi: 10.1016/j.jconrel.2023.03.058</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Mittelstein DR, Ye Jian, Schibber EF, Roychoudhury A, Martinez LT, Fekrazad MH, Ortiz M, et al. Selective ablation of cancer cells with low intensity pulsed ultrasound. Appl Phys Lett. 2020; 116(1): 013701 doi: 10.1063/1.5128627</mixed-citation><mixed-citation xml:lang="en">Mittelstein  DR, Ye  Jian, Schibber  EF, Roychoudhury  A, Martinez LT, Fekrazad MH, Ortiz M, et al. Selective ablation of cancer cells with low intensity pulsed ultrasound. Appl Phys Lett. 2020; 116(1): 013701 doi: 10.1063/1.5128627</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu L, Altman MB, Laszlo A, Straube W, Zoberi I, Hallahan Dennis E, et al. Ultrasound hyperthermia technology for radiosensitization. Ultrasound Med Biol. 2019; 45: 1025-1043. doi: 10.1016/j.ultrasmedbio.2018.12.007</mixed-citation><mixed-citation xml:lang="en">Zhu L, Altman  MB, Laszlo  A, Straube W, Zoberi  I, Hallahan  Dennis  E, et  al. Ultrasound hyperthermia technology for radiosensitization. Ultrasound Med Biol. 2019; 45: 1025-1043. doi: 10.1016/j.ultrasmedbio.2018.12.007</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Schneider CS, Woodworth GF, Vujaskovic Z, Mishra MV. Radiosensitization of high-grade gliomas through induced hyperthermia: Review of clinical experience and the potential role of MR-guided focused ultrasound. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020; 142: 43-51. doi: 10.1016/j.radonc.2019.07.017</mixed-citation><mixed-citation xml:lang="en">Schneider CS, Woodworth GF, Vujaskovic Z, Mishra MV. Radiosensitization of  high-grade gliomas through induced hyperthermia: Review of clinical experience and the potential role of MR-guided focused ultrasound. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020; 142: 43-51. doi: 10.1016/j.radonc.2019.07.017</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">D’Ammando A, Raspagliesi L, Gionso M, Franzini A, Porto E, Di Meco F, et al. Sonodynamic therapy for the treatment of intracranial gliomas. J Clin Med. 2021; 10(5): 1101. doi: 10.3390/jcm10051101</mixed-citation><mixed-citation xml:lang="en">D’Ammando  A, Raspagliesi  L, Gionso  M, Franzini  A, Porto E, Di Meco F, et al. Sonodynamic therapy for the treatment of intracranial gliomas. J Clin Med. 2021; 10(5): 1101. doi: 10.3390/jcm10051101</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Choi V, Rajora MA, Zheng G. Activating drugs with sound: mechanisms behind sonodynamic therapy and the role of nanomedicine. Bioconjugate Chemistry. 2020; 31(4): 967-989.</mixed-citation><mixed-citation xml:lang="en">Choi V, Rajora MA, Zheng G. Activating drugs with sound: mechanisms behind sonodynamic therapy and the role of nanomedicine. Bioconjugate Chemistry. 2020; 31(4): 967-989.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Venter RL. Effects of low intensity bio-resonance focused ultrasound on destroying cancerous cells: A literature review of low intensity bio-resonance focused on destroying cells. IAJPS. 2021; 08(05): 125-144. doi: 10.5281/zenodo.4752632</mixed-citation><mixed-citation xml:lang="en">Venter RL. Effects of low intensity bio-resonance focused ultrasound on destroying cancerous cells: A literature review of low intensity bio-resonance focused on destroying cells. IAJPS. 2021; 08(05): 125-144. doi: 10.5281/zenodo.4752632</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Meng Y, Pople CB, Suppiah S, Llinas M, Huang Y, Sahgal A, et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. Neuro Oncol. 2021; 23(10): 1789-1797. doi: 10.1093/neuonc/noab057</mixed-citation><mixed-citation xml:lang="en">Meng Y, Pople CB, Suppiah S, Llinas M, Huang Y, Sahgal A, et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. Neuro Oncol. 2021; 23(10): 1789-1797. doi: 10.1093/neuonc/noab057</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu L, Nazeri A, Pacia CP, Yue Y, Chen H. Focused ultrasound for safe and effective release of brain tumor biomarkers into the peripheral circulation. PLoS One. 2020; 15(6): e0234182. doi: 10.1371/journal.pone.0234182</mixed-citation><mixed-citation xml:lang="en">Zhu L, Nazeri A, Pacia CP, Yue Y, Chen H. Focused ultrasound for  safe and  effective release of  brain tumor biomarkers into the peripheral circulation. PLoS One. 2020; 15(6): e0234182. doi: 10.1371/journal.pone.0234182</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Pacia CP, Zhu L, Yang Y, Yue Y, Nazeri A, Gach M, et al. Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model. Sci Rep. 2020; 10(1):7449. doi: 10.1038/s41598-020-64440-3</mixed-citation><mixed-citation xml:lang="en">Pacia  CP, Zhu  L, Yang Y, Yue Y, Nazeri  A, Gach  M, et  al. Feasibility and  safety of  focused ultrasound-enabled liquid biopsy in the brain of a porcine model. Sci Rep. 2020; 10(1):7449. doi: 10.1038/s41598-020-64440-3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
